LGMD2B / R2 — Dysferlinopathy

The big picture is shifting Encouraging

The conversation in dysferlinopathy research has moved from “can a treatment be developed?” to “how do we deliver it most effectively?” For a rare disease, that is a meaningful change of stage — multiple teams worldwide are now actively working on it.

Progress on the “large gene” challenge Gene therapy

Dysferlin’s genetic blueprint has long been too big to fit inside the standard delivery vehicle (AAV) used in gene therapy. Several teams are now working to get past that hurdle in different ways:

• Dual-vector strategies — splitting the gene and recombining it inside the cell.
• Split-intein methods — joining the protein back together (research from Kinea Bio and the University of Washington).
• RNA-based recombination — alternative approaches from the Salk Institute and the University of Rochester.
• Myotropic AAVs (MYO-AAVs) — smarter delivery aimed at muscle, needing less virus.

Encouragingly, the FDA recently approved a gene therapy for otoferlin — a protein in the same family as dysferlin, with the same “too-big-to-fit” challenge — using a two-piece delivery method. A different target, but the same hurdle, cleared.

Building the path to clinical trials Trial readiness

• The first Regional Center of Excellence for Dysferlinopathy is being established (University of Texas, San Antonio) — designed so people can take part without having to fly long distances.
• The Dysferlin Registry now has over 1,400 genetically-diagnosed members. A large, engaged registry is one of the strongest signals that encourages companies to invest in a rare disease.

If you or a family member has LGMD2B / R2, joining the registry is one of the most useful steps — it’s how patients are matched to future trials.

Understanding how the disease progresses New research

A 2026 study used AI to combine clinical data with quantitative muscle MRI to better predict how dysferlinopathy progresses. A hopeful detail worth knowing: the disease varies a great deal between people — many remain functional for a very long time, and progression is slow for most.